Drug Type Biosimilar, Monoclonal antibody |
Synonyms Abevmy, Bevacizumab biosimilar, KRABEVA + [3] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date India (01 Jan 2017), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Australia | 06 Sep 2021 | |
Breast cancer recurrent | Australia | 06 Sep 2021 | |
High grade glioma | Australia | 06 Sep 2021 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Australia | 06 Sep 2021 | |
Platinum-Resistant Epithelial Ovarian Carcinoma | Australia | 06 Sep 2021 | |
Platinum-Resistant Fallopian Tube Carcinoma | Australia | 06 Sep 2021 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Australia | 06 Sep 2021 | |
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Australia | 06 Sep 2021 | |
Uterine Cervical Cancer | Australia | 06 Sep 2021 | |
Advanced Renal Cell Carcinoma | European Union | 21 Apr 2021 | |
Advanced Renal Cell Carcinoma | Iceland | 21 Apr 2021 | |
Advanced Renal Cell Carcinoma | Liechtenstein | 21 Apr 2021 | |
Advanced Renal Cell Carcinoma | Norway | 21 Apr 2021 | |
EGFR positive Non-squamous non-small cell lung cancer | European Union | 21 Apr 2021 | |
EGFR positive Non-squamous non-small cell lung cancer | Iceland | 21 Apr 2021 | |
EGFR positive Non-squamous non-small cell lung cancer | Liechtenstein | 21 Apr 2021 | |
EGFR positive Non-squamous non-small cell lung cancer | Norway | 21 Apr 2021 | |
Metastatic breast cancer | European Union | 21 Apr 2021 | |
Metastatic breast cancer | Iceland | 21 Apr 2021 | |
Metastatic breast cancer | Liechtenstein | 21 Apr 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 3 | Belarus | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Bosnia and Herzegovina | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Bulgaria | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Croatia | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Georgia | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Hungary | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | India | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Italy | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Philippines | 21 Jan 2017 | |
metastatic non-small cell lung cancer | Phase 3 | Poland | 21 Jan 2017 |
Phase 3 | 671 | (MYL-1402O) | skxhaixkgk: Risk Ratio (RR) = 0.96 (90% CI, 0.83 - 1.12) | - | 01 Feb 2021 | ||
(Avastin) | |||||||
Phase 3 | metastatic non-small cell lung cancer First line | 671 | gqcytvbfwm(ymmnitwzzo): ratio = 0.96 (90% CI, 0.73 - 1.36); difference = -1.6 (95% CI, -9.0 to 5.9) View more | Positive | 17 Sep 2020 | ||